NO20080626L - Inhibitorer av fibroblastaktiverende protein alfa - Google Patents

Inhibitorer av fibroblastaktiverende protein alfa

Info

Publication number
NO20080626L
NO20080626L NO20080626A NO20080626A NO20080626L NO 20080626 L NO20080626 L NO 20080626L NO 20080626 A NO20080626 A NO 20080626A NO 20080626 A NO20080626 A NO 20080626A NO 20080626 L NO20080626 L NO 20080626L
Authority
NO
Norway
Prior art keywords
protein alpha
inhibitors
activating protein
fibroblast activating
peptide
Prior art date
Application number
NO20080626A
Other languages
English (en)
Inventor
Hung-Sen Lai
William W Bachovchin
Original Assignee
Tufts College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tufts College filed Critical Tufts College
Publication of NO20080626L publication Critical patent/NO20080626L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/04—Esters of boric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/04—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D277/06—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

Angitt er peptid-baserte forbindelser som inkludere borsyre eller cyano funksjonalitet, som effektivt og selektivt inhiberer fibroblast aktiveringsprotein alfa. Blant andre terapeutiske anvendelser kan de peptid-baserte forbindelser være nyttige for behandlingen av cancer.
NO20080626A 2005-07-05 2008-02-04 Inhibitorer av fibroblastaktiverende protein alfa NO20080626L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69677205P 2005-07-05 2005-07-05
PCT/US2006/026258 WO2007005991A1 (en) 2005-07-05 2006-07-05 Inhibitors of fibroblast activation protein alpha

Publications (1)

Publication Number Publication Date
NO20080626L true NO20080626L (no) 2008-04-02

Family

ID=37604810

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20080626A NO20080626L (no) 2005-07-05 2008-02-04 Inhibitorer av fibroblastaktiverende protein alfa

Country Status (12)

Country Link
US (2) US7998997B2 (no)
EP (1) EP1898899A4 (no)
JP (2) JP5229897B2 (no)
KR (1) KR20080030079A (no)
CN (1) CN101247799B (no)
AU (1) AU2006264305B2 (no)
BR (1) BRPI0612607A2 (no)
CA (1) CA2613795A1 (no)
IL (2) IL188327A0 (no)
MX (1) MX2008000318A (no)
NO (1) NO20080626L (no)
WO (1) WO2007005991A1 (no)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006246719A1 (en) * 2005-05-19 2006-11-23 Genentech, Inc. Fibroblast activation protein inhibitor compounds and methods
EP1760076A1 (en) * 2005-09-02 2007-03-07 Ferring B.V. FAP Inhibitors
EP2178888B1 (en) 2007-08-06 2012-07-04 Millennium Pharmaceuticals, Inc. Proteasome inhibitors
US7442830B1 (en) 2007-08-06 2008-10-28 Millenium Pharmaceuticals, Inc. Proteasome inhibitors
US7838673B2 (en) 2007-10-16 2010-11-23 Millennium Pharmaceuticals, Inc. Proteasome inhibitors
JP5600595B2 (ja) * 2007-10-16 2014-10-01 ミレニアム ファーマシューティカルズ， インコーポレイテッド プロテアソーム阻害剤
GEP20135847B (en) 2008-06-17 2013-06-10 Millennium Pharm Inc Boronate ester compounds and pharmaceutical compositions containing them
AR075090A1 (es) 2008-09-29 2011-03-09 Millennium Pharm Inc Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden.
AR080863A1 (es) 2010-03-31 2012-05-16 Millennium Pharm Inc Derivados del acido1-amino-2-ciclopropiletilboronico, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer.
PL2753334T3 (pl) * 2011-08-30 2022-12-12 Trustees Of Tufts College Aktywowane przez fap inhibitory proteasomu do leczenia guzów litych
US9284337B2 (en) * 2011-11-22 2016-03-15 Trustees Of Tufts College Small molecule enhancer for dendritic cell cancer vaccines
US20150202218A1 (en) * 2012-08-02 2015-07-23 Trustees Of Tufts College Broad Spectrum Inhibitors of the Post Proline Cleaving Enzymes for Treatment of Hepatitis C Virus Infections
SG10202003693RA (en) 2014-05-20 2020-05-28 Millennium Pharm Inc Boron-containing proteasome inhibitors for use after primary cancer therapy
CZ2014527A3 (cs) 2014-08-05 2016-02-17 Ústav Organické Chemie A Biochemie Akademie Věd Čr, V.V.I. Způsob detekce aktivní formy analytů ve vzorku a stanovení schopnosti dalších látek vázat se do aktivních míst těchto analytů
MA41505A (fr) 2015-02-11 2017-12-19 Millennium Pharm Inc Nouvelle forme cristalline d'un inhibiteur de protéasome
WO2016171446A1 (ko) * 2015-04-20 2016-10-27 동아에스티 주식회사 펩타이드 붕소산 화합물을 함유하는 안정화 약학 제제
CN106588965A (zh) * 2015-10-15 2017-04-26 北京大学 脲拟肽硼酸化合物及其药物组合物、制备方法和用途
JP6223508B2 (ja) * 2016-06-27 2017-11-01 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． プロテアソーム阻害剤
JP7162592B2 (ja) 2016-12-14 2022-10-28 パーデュー・リサーチ・ファウンデイション 線維芽細胞活性化タンパク質（ｆａｐ）標的イメージングおよび治療
US11613785B2 (en) 2017-01-09 2023-03-28 Onkosxcel Therapeutics, Llc Predictive and diagnostic methods for prostate cancer
CN108929340B (zh) * 2017-05-22 2019-12-13 北京大学 脯氨酸硼酸类化合物及其制备方法和用途
WO2019154859A1 (en) * 2018-02-06 2019-08-15 Universität Heidelberg Fap inhibitor
MX2022011842A (es) 2020-03-24 2022-10-20 Tufts College Agentes de imagen y radiofarmacos dirigidos a fap, y usos relacionados con los mismos.

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US497A (en) * 1837-12-01 Improvement in the machine for preparing ice for shipping and storing
US4935493A (en) * 1987-10-06 1990-06-19 E. I. Du Pont De Nemours And Company Protease inhibitors
US5106948A (en) * 1988-05-27 1992-04-21 Mao Foundation For Medical Education And Research Cytotoxic boronic acid peptide analogs
US5159060A (en) * 1988-05-27 1992-10-27 Mayo Foundation For Medical Education And Research Cytotoxic boronic acid peptide analogs
US4963655A (en) 1988-05-27 1990-10-16 Mayo Foundation For Medical Education And Research Boron analogs of amino acid/peptide protease inhibitors
AU2003219652A1 (en) * 2002-01-08 2003-07-30 Eisai Co. Ltd. Eponemycin and epoxomicin analogs and uses thereof
EP2204181A3 (en) 2002-04-30 2010-09-22 Trustees Of Tufts College Protease inhibitors
CA2491466A1 (en) * 2002-07-09 2004-01-15 Sharlene Adams Methods and compositions relating to isoleucine boroproline compounds
EP1581496A4 (en) * 2002-12-02 2008-04-23 Gilead Sciences Inc 2-SUBSTITUTED 3-PROPENAMIDE DERIVATIVES AND PROCESS FOR THEIR PREPARATION
US7576206B2 (en) * 2003-08-14 2009-08-18 Cephalon, Inc. Proteasome inhibitors and methods of using the same
SI1689757T1 (sl) * 2003-11-12 2015-01-30 Sino-Med International Alliance, Inc. Heterociklične spojine boronske kisline
AU2006246719A1 (en) * 2005-05-19 2006-11-23 Genentech, Inc. Fibroblast activation protein inhibitor compounds and methods

Also Published As

Publication number Publication date
IL188327A0 (en) 2008-04-13
EP1898899A1 (en) 2008-03-19
CA2613795A1 (en) 2007-01-11
US20090221818A1 (en) 2009-09-03
AU2006264305B2 (en) 2012-07-05
JP2012140439A (ja) 2012-07-26
AU2006264305A1 (en) 2007-01-11
JP2009500423A (ja) 2009-01-08
WO2007005991A1 (en) 2007-01-11
US20120077779A1 (en) 2012-03-29
US7998997B2 (en) 2011-08-16
IL217579A (en) 2013-04-30
BRPI0612607A2 (pt) 2010-12-07
EP1898899A4 (en) 2009-07-29
JP5229897B2 (ja) 2013-07-03
MX2008000318A (es) 2008-03-11
KR20080030079A (ko) 2008-04-03
CN101247799A (zh) 2008-08-20
CN101247799B (zh) 2013-03-27

Similar Documents

Publication Publication Date Title
NO20080626L (no) Inhibitorer av fibroblastaktiverende protein alfa
CL2008001234A1 (es) Compuestos derivados de heterociclos nitrogenados, inhibidores de las proteinas de apoptosis; y uso en el tratamiento del cancer.
EA200801301A1 (ru) ИНГИБИТОРЫ АКТИВНОСТИ Akt
CY1115535T1 (el) Αναστολεις δραστικοτητας ακτ
ATE432281T1 (de) Pyrrolotriazin-kinasehemmer
CL2008001633A1 (es) Compuestos derivados de pirrolidin-3-carboxamida; composición farmacéutica; y uso comominhibidores de erk para el tratamiento del cancer.
EA200801430A1 (ru) Производные триазола
BR112012008624A2 (pt) inibidores de tirosina quinase de bruton
BRPI0809583A2 (pt) polipeptídeos fgf-21 modificados e seus usos
JO3235B1 (ar) مركبات بيررولوبيريميدين و استعمالاتها
EA200901313A1 (ru) Ингибиторы тирозинкиназы брутона
EA201000094A1 (ru) Производные пиримидинил-пиридазинона
CY1112206T1 (el) Παραγωγα πυριδαζινονης για την θεραπεια ογκων
ATE524459T1 (de) Pyrazolederivate und ihr einsatz als hemmer von cyclinabhängigen kinasen
DK1866324T3 (da) Phosphoramidatderivater af nukleosidforbindelser til anvendelse i behandlingen af cancer
ECSP088440A (es) Imidazopirazinas como inhibidores de proteinquinasa
CL2011001215A1 (es) Compuestos derivados de pirimidina, inhibidores de tirosina quinasa; composiciones farmaceuticas que los comprenden; y su uso en el tratamiento y/o prevencion de cancer, enfermedades inflamatorias y enfermedades autoinmunes.
CL2011002300A1 (es) Compuestos derivados de 2,4-diamiropirimidinas 5-sustitudas inhibidoras de quinasa ptk2; preparaciones farmaceuticas; y su uso para el tratamiento y/o la prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunes.
CL2008001038A1 (es) Uso de una composicion que comprende un antagonosta h1, y un compuesto anti-tnf alfa para tratar conjuntivitis alegica o rinitis alergiva en un sujeto humano
CL2008002369A1 (es) Compuestos derivados de piridin-3-il-oxipiridin-2-il-amino, inhibidores de alk5; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento del cancer.
CL2007002384A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento de la psoriasis.
NO20061626L (no) Tienopyrazoler
CL2008001373A1 (es) Compuestos derivados de fenilamino-benceno sustituidos; metodo de preparacion; composicion farmaceutica; kit farmceuticos; y uso de dichos compuestos en el tratamiento del cancer.
CL2008000021A1 (es) Compuestos derivados de 2,4-dianilinopirimidinas, inhibidores de proteinas cinasas; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento o prevencion de enfermedades inflamatorias, diabetes y cancer.
WO2009158374A3 (en) Inhibitors of akt activity

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application